Clinical comparison of tofogliflozin and empagliflozin based on an analysis of 24-h accumulated urine in Japanese patients with type 2 diabetes mellitus

Aim In Japan, six sodium-glucose co-transporter 2 inhibitors have been approved for use, and some agents are associated with a significant decrease in cardiovascular events. In this study, the effects of tofogliflozin and empagliflozin were compared. Methods Patients with type 2 diabetes mellitus who were administered tofogliflozin (n = 10) and empagliflozin (n = 12) were extracted. The clinical parameters and 24-h accumulated urine samples before and after 48 weeks were analyzed with generalized linear mixed model. Results Both groups showed significant differences in the following parameters: body weight (p Conclusions The present results indicate that empagliflozin and tofogliflozin influence certain clinical parameters similarly; however, empagliflozin significantly increased the hematocrit than tofogliflozin. Differences in the effects of tofogliflozin and empagliflozin might influence cardiovascular events.